ACPE Continuing Pharmacy Education

This program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon Society of Health-System Pharmacists (OSHP). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. 

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 30 days of program attendance. 

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 30 days of program attendance to ensure awarding of credit. It is the participant's responsibility to check CPE Monitor and ensure credits have successfully uploaded. 

Target Audience: Pharmacists and Pharmacy Technicians
Total Credits Available: 12 hours (1.2 CEUs)
Conflict of Interest Disclosures: Shannon O’Hara has a conflict of interest with Novo Nordisk, Inc. Rachel Chlasta has a conflict of interest with Medtronic. YoungYoon Ham has a conflict of interest with Gilea Science, Inc. These relationships have all been mitigated for this program. All other speakers and planners for this program have no financial relationships with ineligible companies to disclose.

The Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and self-assessment test located at https://pharmacy.oregonstate.edu/ce within 30 days of attendance. 

Title: Poster-to-Podium
UAN: 0036-9999-24-200-L01-P/T
Date & Time: 4/26/2024, 2:00-3:00 pm
Speakers: Bryce Ashby, PharmD, Legacy Health, Clinical Pharmacist; Justin Donat, PharmD, MBA, MS, Providence Health & Services, PGY-1 Pharmacy Resident; Vy Nguyen-Tran, MBA, PharmD Candidate, OSU/OHSU College of Pharmacy; Kalina Michel Rivera, PharmD, Legacy Health, PGY1 Pharmacy Resident;
Activity-Type: Knowledge-based
Topic Designation: Disease State Management/Drug Therapy
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:

1. (Ashby) Explore what is currently known about genitourinary infection risk for patients taking SGLT2i
2. (Ashby) Describe the genitourinary infection rates observed in patients taking SGLT2i within a population-based retrospective study
3. (Donat) Discuss the clinical impacts of AUC-guided vancomycin monitoring
4. (Donat) Describe the effects of vancomycin monitoring protocols on pharmacy operations
5. (Nguyen-Tran) Identify 2 PHQI gaps in Oregon pharmacy practice
6. (Rivera) Review current recommendations on aspirin use for primary prevention of clinical ASCVD events
7. (Rivera) Identify patients eligible for discontinuation of aspirin use for primary prevention of ASCVD events

CPT Learning Objectives:

1. (Ashby) Explore what is currently known about genitourinary infection risk for patients taking SGLT2i
2. (Ashby) Describe the genitourinary infection rates observed in patients taking SGLT2i within a population-based retrospective study
3. (Donat) Recognize a common side effect of vancomycin
4. (Donat) Interpret how narrow therapeutic index of vancomycin affects pharmacy operations
5. (Nguyen-Tran) Identify 2 PHQI gaps in Oregon pharmacy practice that technicians can address to improve patient safety and quality assurance
6. (Rivera) Review current recommendations on aspirin use for primary prevention of clinical ASCVD events

Title: Precepting: Challenging Issues and Giving and Receiving Feedback
UAN: 0036-9999-24-201-L99-P/T
Date & Time: 4/26/2024, 3:10-5:10 pm
Speakers: Madeline Fry, BCACP, Pacific University School of Pharmacy; Dana Hammer, RPh, MS, PhD, FNAP, University of Colorado Skaggs School of Pharmacy, Senior Instructor and Faculty Lead for Student Professional Development; Sue Stein, DHEd, MS, RPh, FNAP, FOSHP, Pacific University, Professor Emeritus & SMSC, LLC Managing Member
Activity-Type: Application-based
Topic Designation: Additional Topic Areas
Credit Hours: 2.0 (0.2 CEUs)
Learning Objectives:

1. Describe the entrustment scale and EPAs as a tool for formative based assessment of learning
2. Use the entrustment scale to evaluate mock scenarios
3. Describe best practices for providing feedback such as the Pendleton Model, Coaching, and Crucial Conversations
4. Practice these strategies with mock scenarios

Title: Addressing the Decline in Pharmacy School Enrollment Rates and How That will Translate to Future Practice
UAN: 0036-9999-24-202-L99-P/T
Date & Time: 4/27/24, 8:30-9:30 am
Speakers: Juancho Ramirez, PharmD, OSU College of Pharmacy; Andrew Jarrel, PharmD, BCCCP, Provide St Vincent Medical Center, Manager, Clinical Pharmacy Services, Residency Program Director, PGY1 Pharmacy; Samantha Muir, PharmD, BCPS, Sky Lakes Medical Center, Residency Program Director, Retail Pharmacy Manager; Brandon Nuziale, PharmD, BCACP, Pacific University School of Pharmacy, Assistant Dean for Student Affairs; Katie Yabut, PharmD, BCPS, Legacy Health Clinical Pharmacy Manager and Residency Program Director
Activity-Type: Knowledge-based
Topic Designation: Additional Topic Areas
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Discuss the current trend in pharmacy school enrollment and subsequent impact on post graduate training and workforce characteristics
2. Identify strategies for engaging with current learners and mechanisms to ensure a steady stream of future pharmacist practitioners

Title: Gender Diversity and Providing Culturally Competent Transgender Health Services
UAN: 0036-9999-24-203-L99-P/T
Date & Time: 4/27/24, 9:45-10:45 am
Speakers: Rook Bartz, RN BSN, Legacy Health, Program Manager, Gender & Sexual Health
Activity-Type: Knowledge-based
Topic Designation: Additional Topic Areas (CULTURAL COMPETENCE)
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Discuss the language patients use to refer to themselves; avoid outdated terms
2. Practice inclusive communication
3. Express affirming support in at least 2 physical ways in the pharmacy
4. Implement policies that reduce bias and/or discrimination
5. Analyze the challenges that exist for pharmacists and technicians to provide care to this community

Title: Beyond the ABC’s: A Review of Pharmacotherapeutic Options for Adiposity-Based Chronic Disease
UAN: 0036-9999-24-204-L01-P and 0036-9999-24-205-L01-T
Date & Time: 4/27/2024, 2:00-3:00 pm
Speakers: Rachel Chlasta, PharmD, BCACP, CDCES, Legacy Health, Clinical Pharmacist, Endocrinology and Population Health; Jessica Potter, PharmD, BCACP, Legacy Medical Group, Ambulatory Care Pharmacist
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Topic Designation: Disease State Management/Drug Therapy
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:

1. Analyze patient-specific factors to determine which patients are indicated for weight-management pharmacotherapy
2. Compare the safety and efficacy of agents indicated for weight-management pharmacotherapy
3. Given a case scenario, design a treatment plan for a patient with ABCD

CPT Learning Objectives:

1. List which medications are indicated for weight management
2. Recall contraindications of anti-obesity medications (AOMs)
3. Recognize strategies for lowering a patient’s out-of-pocket cost for AOM 

Title: Hepatitis C Treatment and Beyond: Updates and Future Directions
UAN: 0036-9999-24-206-L01-P/T
Date & Time: 4/27/2024, 2:00-3:00pm
Speakers: YoungYoon Ham, PharmD, BCIDP, OHSU, Infectious Disease and Allergy Pharmacist
Activity-Type: Knowledge-based
Topic Designation: Disease State Management/Drug Therapy
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Recognize changes to hepatitis C testing in most recent guidelines updates
2. Describe changes to hepatitis treatment in most recent guidelines updates
3. Review literature on innovative ways to reach and treat patients with this disease state 

Title: Neuropsychiatric Complications of B Vitamin Deficiencies
UAN: 0036-9999-24-207-L01-P and 0036-9999-24-208-L01-T
Date & Time: 4/27/2024, 3:05-4:05 pm
Speakers: Marketa Marvanova, PharmD, PhD, BCGP, BCPP, FASCP, Pacific University, School of Pharmacy, Dean, Professor
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Topic Designation: Disease State Management/Drug Therapy
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:

1. Recognize presentation of various neurologic and psychiatric complications associated with deficiency of B1, B3, B5, B6, B9, and B12 vitamins and the common causes for these deficiencies
2. Compare and contrast clinical presentation, time course, and laboratory assessment of vitamin B9 and B12 deficiencies
3. Compare and contrast Wernicke encephalopathy with Wenicke-Korsakoff syndrome in terms of clinical course, clinical presentation, and treatment
4. Given a patient case or clinical scenario, identify vitamin deficiency and recommend appropriate treatment

CPT Learning Objectives:

1. Recognize presentation of various neurologic and psychiatric complications associated with deficiency of B1, B3, B5, B6, B9, and B12 vitamins and the common causes for these deficiencies
2. Discuss clinical presentation, time course, and laboratory assessment of vitamin B9 and B12 deficiencies
3. Describe Wernicke encephalopathy and Wenicke-Korsakoff syndrome in terms of clinical course, clinical presentation, and treatment

Title: Artificial Intelligence and ChatGPT: Effects on Pharmacy Practice
UAN: 0036-9999-24-209-L99-P/T
Date & Time: 4/27/2024, 3:05-4:05 pm
Speakers: Stacey Olstad, PharmD, MBA, OSU College of Pharmacy, Instructor in Pharmacy Practice
Activity-Type: Application-based
Topic Designation: Additional Topic Areas
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Recognize the benefits and limitations of AI and ChatGPT in pharmacy
2. Describe 3 uses for ChatGPT in pharmacy
3. Practice writing good prompts for ChatGPT

Title: Sugar, We’re Going Down: Diabetes and HIV
UAN: 0036-9999-24-210-L02-P/T
Date & Time: 4/27/2024, 4:10-5:10 pm
Speakers: Kendall J. Tucker, PharmD, MS, BCPS, BCIDP, Clinical Assistant Professor
Activity-Type: Knowledge-based
Topic Designation: HIV/AIDS
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:

1. Recognize the epidemiology and importance of diabetes in persons living with HIV
2. Discuss mechanisms and risk factors associated with development of diabetes in persons living with HIV
3. Recommend the best non-pharmacologic or pharmacologic treatment of diabetes for persons living with HIV

CPT Learning Objectives:

1. Recognize the epidemiology and importance of diabetes in persons living with HIV
2. Discuss mechanisms and risk factors associated with development of diabetes in persons living with HIV
3. Recall pharmacologic treatments used for diabetes for persons living with HIV

Title: USP 6 Month Check-In
UAN: 0036-9999-24-211-L07-P/T
Date & Time: 4/27/24, 4:10-5:10 pm
Speakers: Shannon Buxell, PharmD, MPH, BCSCP, Providence St Joseph Health System, Director of Operations & Regulatory, System Pharmacy; Jenni Nelson, PharmD, Kaiser Westside Medical Center, Inpatient Pharmacy Manager; Cassy Robertson-Binkley, PharmD, MBA, BCPS, OHSU, Inpatient Pharmacy Operations Manager
Activity-Type: Knowledge-based
Topic Designation: Compounding
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Describe the ways in which beyond-use-dates are applied to compounded stock solutions
2. Explain the new cleaning requirements, specifically the agents and their dwell times
3. Discuss the variety of ways healthcare systems are developing their assessments of risk for hazardous medication handling

Title: Clinical Pearls
UAN: 0036-9999-24-212-L01-P/T
Date & Time: 4/28/24, 8:00-9:00 am
Speakers: Jason Hector, PharmD Candidate, Kaiser Permanente, Inpatient Pharmacy Student Intern; Y.B. Ly, Roseburg VA Medical Center; Tung T. Pham, PharmD, Roseburg VA Health Care System; Rochelle Taicz, PharmD, Roseburg VA Health Care System, Pharmacy Resident
Activity-Type: Knowledge-based
Topic Designation: Disease State Management/Drug Therapy
Credit Hours: 1.0 (0.1 CEUs)
RPh Learning Objectives:

1. (Hector) Describe the interaction between hydroxocobalamin and dialysis machines in critically ill patients
2. (Ly) Identify the benefits of integrating buprenorphine treatment within the primary care setting
3. (Pham) Describe the current data surrounding home HbA1c test kids and identify which home A1c test kit is currently NGSP
4. (Taicz) Recognize the variable half-life of long-acting cabotegravir
5. (Taicz) Discuss safe discontinuation methods for long-acting cabotegravir for patients still at high risk of contracting HIV

CPT Learning Objectives:

1. (Hector) Identify the types of interactions that can exist between hydroxocobalamin and dialysis machines in critically ill patients
2. (Ly) Identify the benefits of integrating buprenorphine treatment within the primary care setting
3. (Pham) Describe the current data surrounding home HbA1c test kids and identify which home A1c test kit is currently NGSP
4. (Taicz) Recognize that patients can move their scheduled appointment for an injection up to 7 days early or late and still be considered adherent to the regimen
5. (Taicz) Explain to patients that a confirmed negative HIV test is required prior to every long-acting cabotegravir administration

Title: Buprenorphine for Opioid Use Disorder
UAN: 0036-9999-24-213-L08-P/T
Date & Time:  4/28/24, 9:05-10:05 am
Speakers: Emily Skogrand, PharmD, OHSU, Clinical Pharmacist
Activity-Type: Knowledge-based
Topic Designation: Opioids/Pain Management/Substance Use Disorder
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Review how illicit fentanyl complicates buprenorphine transitions
2. Review acute opioid withdrawal managements of hospitalized patients
3. Describe different methods of transitioning hospitalized patients with an opioid use disorder to buprenorphine

Title: Medication Safety Debates: Balancing Safety with Operational Perspective
UAN: 0036-9999-24-214-L05-P/T
Date & Time: 4/28/24, 10:10-11:10 am
Speakers: Jodi Longueil, PharmD, Kaiser Permanente Northwest, Medication Safety Coordinator; Debbie Viegas, RPh, Kaiser Permanente, Coordinator Pharmacy Quality and Medication Safety
Activity-Type: Knowledge-based
Topic Designation: Patient Safety
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. List features of a Just Culture
2. Identify the difference between high, medium, and low leverage error reduction strategies
3. Discuss strategy limitations with each level 

Title: Oregon Board of Pharmacy Law Update: Inspections & Regulations
UAN: 0036-9999-24-215-L03-P/T
Date & Time: 4/28/2024, 11:20-12:20 pm
Speakers: Jennifer L. Davis, PharmD, MS, BCACP, RPh, OBOP; Jane Lee, PharmD, RPh, OBOP, Compliance Officer
Activity-Type: Knowledge-based
Topic Designation: Law Related to Pharmacy Practice
Credit Hours: 1.0 (0.1 CEUs)
Learning Objectives:

1. Discuss new laws as well as current and proposed rules related to Oregon pharmacy practice
2. Analyze recent legislative changes and proposed rule amendments affecting pharmacy practice in Oregon
3. Review compliance expectations for existing laws and rules created to ensure safe and effective delivery of care
4. Describe the purpose of inspections and what to expect during the inspection process
5. Develop strategies to utilize the Board of Pharmacy’s available resources